Endometrial Cancer: Future Directions and Unmet Needs

Video content above is prompted by the following:

This segment explores cutting-edge antibody-drug conjugate (ADC) development in endometrial cancer, featuring 2 particularly promising agents targeting novel tumor antigens. The discussion highlights B7-H4-targeting ADCs with topoisomerase I payloads, showing impressive response rates of 30% to 40% with manageable toxicity profiles. These agents represent the evolution of ADC technology, moving beyond established targets to explore new therapeutic opportunities with potentially improved efficacy and safety profiles.

The conversation also covers folate receptor–targeting ADCs, which have demonstrated response rates approaching 50% in patients with heavily pretreated endometrial cancer. These unprecedented response rates in recurrent endometrial cancer represent a dramatic improvement over historical outcomes, with experts noting the factual accuracy of describing these results as truly unprecedented. The discussion acknowledges the challenge of managing multiple new therapeutic options while ensuring patient safety through appropriate monitoring and supportive care strategies.

Looking toward the future, the panel expresses excitement about several emerging trends in endometrial cancer treatment. These include hormone receptor–targeted therapies adapted from breast cancer advances, PI3-kinase and AKT inhibitors for hormonally driven tumors, and innovative approaches like microbiome optimization to enhance immunotherapy responses. The conversation concludes with acknowledgment of the rapidly evolving treatment landscape, emphasizing the challenge for clinicians to stay current with advancing therapeutic options while maintaining focus on optimal patient care and outcomes. The segment underscores the transformation of endometrial cancer from a disease with limited options to one with multiple targeted therapeutic approaches.